LeMaitre Vascular, Inc. (NASDAQ:LMAT) Earns Among The Best Returns In Its Industry

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Today we are going to look at LeMaitre Vascular, Inc. (NASDAQ:LMAT) to see whether it might be an attractive investment prospect. To be precise, we’ll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business.

First up, we’ll look at what ROCE is and how we calculate it. Next, we’ll compare it to others in its industry. Finally, we’ll look at how its current liabilities affect its ROCE.

Understanding Return On Capital Employed (ROCE)

ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. In general, businesses with a higher ROCE are usually better quality. Overall, it is a valuable metric that has its flaws. Renowned investment researcher Michael Mauboussin has suggested that a high ROCE can indicate that ‘one dollar invested in the company generates value of more than one dollar’.

So, How Do We Calculate ROCE?

Analysts use this formula to calculate return on capital employed:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

Or for LeMaitre Vascular:

0.14 = US$20m ÷ (US$160m – US$19m) (Based on the trailing twelve months to March 2019.)

So, LeMaitre Vascular has an ROCE of 14%.

See our latest analysis for LeMaitre Vascular

Is LeMaitre Vascular’s ROCE Good?

One way to assess ROCE is to compare similar companies. LeMaitre Vascular’s ROCE appears to be substantially greater than the 10% average in the Medical Equipment industry. I think that’s good to see, since it implies the company is better than other companies at making the most of its capital. Separate from LeMaitre Vascular’s performance relative to its industry, its ROCE in absolute terms looks satisfactory, and it may be worth researching in more depth.

NasdaqGM:LMAT Past Revenue and Net Income, June 13th 2019
NasdaqGM:LMAT Past Revenue and Net Income, June 13th 2019

It is important to remember that ROCE shows past performance, and is not necessarily predictive. ROCE can be deceptive for cyclical businesses, as returns can look incredible in boom times, and terribly low in downturns. ROCE is only a point-in-time measure. Future performance is what matters, and you can see analyst predictions in our free report on analyst forecasts for the company.

What Are Current Liabilities, And How Do They Affect LeMaitre Vascular’s ROCE?

Current liabilities are short term bills and invoices that need to be paid in 12 months or less. The ROCE equation subtracts current liabilities from capital employed, so a company with a lot of current liabilities appears to have less capital employed, and a higher ROCE than otherwise. To counteract this, we check if a company has high current liabilities, relative to its total assets.

LeMaitre Vascular has total assets of US$160m and current liabilities of US$19m. As a result, its current liabilities are equal to approximately 12% of its total assets. Current liabilities are minimal, limiting the impact on ROCE.

Our Take On LeMaitre Vascular’s ROCE

Overall, LeMaitre Vascular has a decent ROCE and could be worthy of further research. LeMaitre Vascular looks strong on this analysis, but there are plenty of other companies that could be a good opportunity . Here is a free list of companies growing earnings rapidly.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.